GENISTEIN ALLEVIATES HIGH GLUCOSE INDUCED TOXICITY AND ANGIOGENESIS IN CULTURED HUMAN RPE CELLS

  • Shirish Dongare Ocular Pharmacology Laboratory, Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
  • Sharmila Rajendran Department of Ocular Pharmacology, Aravind Medical Research Foundation, Madurai (TN), India
  • S. Senthilkumari Department of Ocular Pharmacology, Aravind Medical Research Foundation, Madurai (TN), India
  • Suresh K. Gupta Dept. of Ocular Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, New Delhi
  • Rajani Mathur Ocular Pharmacology Laboratory, Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
  • Rohit Saxena Dr. R.P. Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
  • Sushma Srivastava Ocular Pharmacology Laboratory, Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India

Abstract

Objective: Genistein, an iso flavonoid has been shown to possess many biological activities including anti-inflammatory, antioxidant and anti-angiogenic property. It has been shown to be protective in dampening diabetes induced retinal inflammation in vivo. Therefore, the purpose of the present study is to investigate the effect of genistein on glucose induced toxicity in cultured human RPE cells (ARPE-19).

Methods: ARPE-19 cells were challenged with normal glucose (NG 5 mM) and high glucose (HG1 25 mM & HG2 50 mM) concentrations with or without genistein (20 µM) for 24 h. The mRNA expression of aldose reductase (ALR) and VEGF was measured by real-time PCR using SYBR green. Inhibitory effects upon ALR activity were performed. The VEGF levels of cell supernatant were estimated by sandwich ELISA. Cellular viability and mitochondrial function upon genistein treatment were assessed using dye exclusion method and MTT assay respectively.

Results: Genistein at the studied concentration showed 93% of cell viability and no marked toxicity was observed on cell growth. ARPE-19 cells challenged with HG1 and HG2 showed (2.32) and (2.48) fold increase in ALR expression as compared to NG. Significant increase in VEGF165 expression was observed in ARPE-19 cells with HG1 and HG2 as compared to NG. The genistein treated cells significantly reduced the mRNA expression of both ALR and VEGF165. No significant increase in VEGF level was observed in ARPE-19 cell supernatant with HG1 and HG2 (220.68±5.24 and 228.96±7.19 pg/ml) as compared to NG (220.30±2.04 pg/ml), however, significant reduction was observed in response to treatment with genistein in HG1 and HG2 (155.51±9.33 and 122.85±4.76 pg/ml). Also ALR activity significantly reduced in genistein treated cells when compared with HG1 and HG2 concentrations.

Conclusion: The results of the present study clearly demonstrate that genistein protects RPE cells from glucose toxicity. Genistein could be a prospective potent agent for treating complications linked with diabetes mellitus, such as diabetic retinopathy.

 

Keywords: Aldose reductase, Blood retinall barrier, Retinal Pigment epithelial (RPE) Cells, Diabetic retinopathy, Genistein, VEGF

Downloads

Download data is not yet available.

References

1. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007;10:103-17.
2. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85:845-81.
3. Kim YS, Jung DH, Kim NH, Lee YM, Jang DS, Song GY, et al. KIOM-79 inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. J Ethnopharmacol 2007;112:166-72.
4. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135–44.
5. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001;158:1161–72.
6. Anil Kumar P, Bhanuprakash Reddy G. Focus on molecules: aldose reductase. Exp Eye Res 2007;85:739-40.
7. Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal vascular disease. Ophthalmologica 2010;224(Suppl 1):16-24.
8. Park j, Kim H, Park SY, Lim SW, Kim YS, Lee DH, Roh GS, et al. Tonicity-responsive enhancer binding protein regulates the expression of aldose reductase and protein kinase C δ in a mouse model of diabetic retinopathy. Exp Eye Res 2014;122:13-9.
9. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003;14:233-6.
10. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA. Electron microscopic immunocytochemical demonstration of blood–retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. Histochem J 1993;25:648–63.
11. Henry DN, Frank RN, Hootman SR, Rood SE, Heilig CW, Busik JV. Glucose-specific regulation of aldose reductase in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Visual Sci 2000;41:1554-60.
12. Ganz MB, Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am J Physiol Endocrinol Metab 2000;278:146-52.
13. Glogowski EA, Tsiani E, Zhou X, Fantus IG, Whiteside C. High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Kidney Int 1999;55:486-99.
14. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997;81:363-71.
15. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806–14.
16. Thurston G, Gale NW. Vascular endothelial growth factor and other signaling pathways in developmental and pathologic angiogenesis. Int J Hematol 2004;80:7–20.
17. Le Goff MM, Sutton MJ, Slevin M, Latif A, Humphries MJ, Bishop PN. Opticin exerts its anti-angiogenic activity by regulating extracellular matrix adhesiveness. J Biol Chem 2012;33:28027-36.
18. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10–4.
19. Ford KM, D’Amore PA. Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium. Mol Visual 2012;18:519–27.
20. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592–5.
21. Naderi GA, Asgary S, Sarraf-Zadegan N. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol Cell Biochem 2003;246:193–6.
22. Barnes S. Soy isoflavones phystoestrogens and what else? J Nutr 2004;134:1225S–8S.
23. Fournier DB, Erdman JW Jr, Gordon GB. Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev 1998;7:1055–65.
24. Park CE, Yun H, Lee EB, Min BI, Bae H, Choe W, et al. The antioxidant effects of genistein are associated with AMP-activated protein kinase activation and PTEN induction in prostate cancer cells. J Med Food 2010;13:815–20.
25. Choi MS, Jung UJ, Yeo J, Kim MJ, Lee MK. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab Res Rev 2008;24:74-81.
26. Farina HG, Pomies M, Alonso DF, Gomez DE. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 2006;16:885-91.
27. Ibrahim AS, El-Shishtawy MM, Peña JA, Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vision 2010;16:2033-42.
28. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol 2001; doi: 10.1002/0471142735.ima03bs21. [Article in Press].
29. Ballinger SW, Van Houten B, Jin GF, Conklin CA, Godley BF. Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells. Exp Eye Res 1999;68:765–72.
30. Reddy GB, Satyanarayana A, Balakrishna N, Ayyagari R, Padma M, Viswanath K, et al. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol Vision 2008;14:593-601.
31. Xu HZ, Song Z, Fu S, Zhu M, Le YZ. RPE barrier breakdown in diabetic retinopathy: seeing is believing. J Ocul Biol Dis Infor 2011;4:83-92.
32. Gilbert ER, Liu D. Anti-diabetic functions of soy isoflavone genistein: mechanisms underlying its effects on pancreatic β-cell function. Food Funct 2013;4:200-12.
33. Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA. Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway. Diabetes 2006;55:1043-50.
34. Kowluru RA, Chan Pooi-See. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007: doi: 10.1155/2007/43603. [Article in Press].
35. Mansour MA. Aldose reductase in the retina. Curr Enzyme Inhib 2007;3:1-12.
36. Akamine EH, Hohman TC, Nigro D, Carvalho MH, de Cássia Tostes R, Fortes ZB. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther 2003;304:1236–42.
37. Sun W, Gerhardinger C, Dagher Z, Hoehn T, Lorenzi M. Aspirin at lowintermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 2005;54:3418–26.
38. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006;55:2757–62.
39. Jang DS, Kim JM, Lee YM, Kim YS, Kim H, Kim JS. Puerariafuran, a new inhibitor of advanced glycation end products (AGEs) isolated from the roots of Pueraria lobata. Chem Pharm Bull 2006;54:1315–7.
40. Kim YS, Kim NH, Jung DH, Jang DS, Lee YM, Kim JM, et al. Genistein inhibits aldose reductase activity and high glucose-induced TGF-β2 expression in human lens epithelial cells. Eur J Pharmacol 2008;594:18–25.
41. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 2009;41:2368–71.
42. Kroll P, Rodrigues EB, Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica 2007;221:78–94.
43. Kumar B, Gupta SK, Nag TC, Srivastava S, Saxena R, Jha KA, et al. Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp Eye Res 2014;125:193-202.
44. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J 2013;7:4-10.
45. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996;271:2746-53.
46. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Visual Sci 2006;47:5106–15.
47. Kumar B, Gupta SK, Srinivasan BP, Nag T, Srivastava S, Saxena R. Hesperetin ameliorates hyperglycemia induced retinal vasculopathy via anti-angiogenic effects in experimental diabetic rats. Vasc Pharmacol 2012;57:201–7.
48. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999;274:23463-7.
49. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
50. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 2007;85:762-71.
51. Kim H, Choi JS, Kim KS, Yang JA, Joo CK, Hahn SK. Flt1 peptide–hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta Biomaterialia Biomater 2012;8:3932–40.
Statistics
326 Views | 286 Downloads
How to Cite
Dongare, S., S. Rajendran, S. Senthilkumari, S. K. Gupta, R. Mathur, R. Saxena, and S. Srivastava. “GENISTEIN ALLEVIATES HIGH GLUCOSE INDUCED TOXICITY AND ANGIOGENESIS IN CULTURED HUMAN RPE CELLS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 8, June 2015, pp. 294-8, https://innovareacademics.in/journals/index.php/ijpps/article/view/6446.
Section
Original Article(s)